Cargando…
Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro
BACKGROUND: Imatinib mesylate has significantly improved survival and quality of life of patients with gastrointestinal stromal tumors (GISTs). However, the molecular mechanism through which imatinib exerts its anti-tumor effects is not clear. Previously, we found up-regulation of insulin-like growt...
Autores principales: | Dupart, Jheri J, Trent, Jonathan C, Lee, Ho-Young, Hess, Kenneth R, Godwin, Andrew K, Taguchi, Takahiro, Zhang, Wei |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780392/ https://www.ncbi.nlm.nih.gov/pubmed/19903356 http://dx.doi.org/10.1186/1476-4598-8-99 |
Ejemplares similares
-
Gastrointestinal stromal tumor and its targeted therapeutics
por: Dupart, Jheri, et al.
Publicado: (2011) -
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013) -
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008) -
Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor
por: Quezada, Nicolás, et al.
Publicado: (2014) -
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)